<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631827</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.693</article-id><article-id pub-id-type="publisher-id">ofx163.693</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tebas</surname><given-names>Pablo</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Christine C</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Muthumani</surname><given-names>Kar</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Reuschel</surname><given-names>Emma</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Scott</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Amir S</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Racine</surname><given-names>Trina</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Hyeree</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Zaidi</surname><given-names>Faraz</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Boyer</surname><given-names>Jean</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Kudchodkar</surname><given-names>Sagar</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Young K</given-names></name><degrees>JD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Trottier</surname><given-names>Sylvie</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Remigio</surname><given-names>Celine</given-names></name><degrees>DPT, RN</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Krieger</surname><given-names>Diane</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Kobinger</surname><given-names>Gary P</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Weiner</surname><given-names>David</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Maslow</surname><given-names>Joel</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>University of Penn./Div of Infect Dis, Perelman School of Medicine, University of Pennsylvania</institution>, <addr-line>Philadelphia, Pennsylvania</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>GeneOne Life Sciences</institution>, <addr-line>Philadelphia, Pennsylvania</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Wistar Institute</institution>, <addr-line>Philadelphia, Pennsylvania</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Inovio</institution>, <addr-line>Philadelphia, Pennsylvania</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Public Health Agency of Canada</institution>, <addr-line>Quebec City, QC</addr-line>, <country>Canada</country></aff><aff id="AF0006">
<label>6</label>
<institution>Centre Hospitalier Universitaire de Quebec</institution>, <addr-line>Quebec City, QC</addr-line>, <country>Canada</country></aff><aff id="AF0007">
<label>7</label>
<institution>Miami Research Associates</institution>, <addr-line>Miami, Florida</addr-line></aff><aff id="AF0008">
<label>8</label>
<institution>University of Laval</institution>, <addr-line>Quebec City, QC</addr-line>, <country>Canada</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 78. Zika&#x000a0;Virus</p><p>
<italic>Thursday, October 5, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S300</fpage><lpage>S301</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.693.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barr&#x000e9; syndrome are well-described. There are no therapies or vaccines against ZIKV infection.</p></sec><sec id="s2"><title>Methods</title><p>ZIKA-001 is a phase I, open label, clinical trial designed to evaluate the safety, side effect profile, and immunogenicity of a synthetic, DNA vaccine (GLS-5700) targeting the pre-membrane+envelope proteins (prME) of the virus. Two groups of 20 participants received GLS-5700 at one of two dose levels: 1&#x000a0;mg or 2&#x000a0;mg DNA/dose at 0, 4, and 12 weeks. Vaccine was administered as 0.1 or 0.2&#x000a0;ml (1 or 2&#x000a0;mg) intradermal (ID) injection followed by electroporation (EP) with the CELLECTRA<sup>&#x000ae;</sup>-3P&#x000a0;device</p></sec><sec id="s3"><title>Results</title><p>The median age of the 40 participants was 38 (IQR 30&#x02013;54) years; 60% were female 30% Latino and 78% white. No SAEs have been reported to date. Local minor AEs were injection site pain, redness, swelling and itching that occurred in half of the participants. Systemic adverse events were rare and included headache, myalgias, upper respiratory infections, fatigue/malaise and nausea.</p><p>Four weeks after the first dose 25% vs. 60% of the participants in the 1&#x000a0;mg and 2&#x000a0;mg dose seroconverted. By week 6, 2 weeks after the second dose, the response was 65 and 84% respectively and 2 weeks after the third dose all participants in both dosing groups developed antibodies. At the end of the vaccination period over 60% of vaccinated person neutralized Zika virus in a vero cell assay and greater than 80% on neuronal cell targets. The protective efficacy of the antibodies generated by the vaccine was evaluated in the lethal IFNAR&#x02212;/&#x02212; mouse model. After the intraperitoneal administration of 0.1&#x000a0;ml of either baseline, week 14 serum or PBS the animals were challenged with 10<sup>6</sup> PFUs of ZIKV PR209 isolate. Whereas animals administered PBS (control) or baseline serum succumbed after a median of 5&#x000a0;days, those pretreated with week 14 serum from study participants survived suggesting that the humoral response generated by the vaccine is protective in this&#x000a0;model.</p></sec><sec id="s4"><title>Conclusion</title><p>Our trial shows for the first time in humans the safety and immunogenicity of an engineered DNA encoding consensus viral protein against ZIKV. Future studies will evaluate the effectiveness of the vaccine.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0291"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>C.&#x000a0;C. Roberts</bold>, GeneOne: Member, Salary. <bold>S. White</bold>, GeneOne: Member, Salary. <bold>A. S.&#x000a0;Khan</bold>, Inovio: Employee and Shareholder, Salary and Stock. <bold>J. Boyer</bold>, Inovio: Employee and Shareholder, Salary and Stock. <bold>Y. K.&#x000a0;Park</bold>, GeneOne: Board Member, CEO and Employee, Salary and Stock. <bold>S. Trottier</bold>, Canadian Institutes of Health Research: Investigator, Research grant. <bold>C. Remigio</bold>, GeneOne: Employee and Shareholder, Salary and Stock. <bold>G. P.&#x000a0;Kobinger</bold>, GeneOne: Grant Investigator and Scientific Advisor, Grant recipient and Research support. <bold>D. Weiner</bold>, GeneOne: Grant Investigator and Scientific Advisor, Grant recipient, Licensing agreement or royalty and Stock. <bold>J. Maslow</bold>, GeneOne: Employee, Salary and Stock.</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>